医学
药品
重症监护医学
肝衰竭
肝损伤
病因学
肝损伤
药物反应
不利影响
内科学
药理学
作者
Carla Colaci,Manuel Mendizábal,Fernando Bessone
出处
期刊:Current Drug Safety
[Bentham Science]
日期:2019-02-15
卷期号:14 (2): 94-101
被引量:8
标识
DOI:10.2174/1574886314666190215115434
摘要
Idiosyncratic Drug Induced Liver Injury (DILI) is a rare adverse event to drugs that occasionally leads to severe liver damage, being one of the leading causes of Acute Liver Failure (ALF) in developed countries. DILI is largely a diagnosis of exclusion.Careful history of drug taking and ruling out other competing etiologies is mandatory given that DILI can present with an extremely variable phenotype. Several prognostic scores have been developed to promptly identify patients with potential risk of developing ALF. New biomarkers to diagnose and predict DILI evolution are under study and hopefully we will benefit from these novel tools in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI